Becton, Dickinson and Company $BDX Shares Bought by Flagship Harbor Advisors LLC

Flagship Harbor Advisors LLC lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 144.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,317 shares of the medical instruments supplier’s stock after acquiring an additional 2,552 shares during the period. Flagship Harbor Advisors LLC’s holdings in Becton, Dickinson and Company were worth $744,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BDX. Brighton Jones LLC boosted its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in Becton, Dickinson and Company by 33.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 61,020 shares of the medical instruments supplier’s stock valued at $13,793,000 after purchasing an additional 15,228 shares in the last quarter. Private Trust Co. NA grew its holdings in Becton, Dickinson and Company by 3.9% during the 1st quarter. Private Trust Co. NA now owns 3,866 shares of the medical instruments supplier’s stock valued at $886,000 after purchasing an additional 145 shares in the last quarter. Hudson Edge Investment Partners Inc. acquired a new stake in Becton, Dickinson and Company during the 1st quarter valued at $6,701,000. Finally, Revisor Wealth Management LLC acquired a new stake in Becton, Dickinson and Company during the 1st quarter valued at $477,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 1,895 shares of company stock valued at $358,995. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $179.07 on Friday. The business’s fifty day moving average price is $188.79 and its 200 day moving average price is $183.36. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The stock has a market capitalization of $51.33 billion, a PE ratio of 32.21, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.32 billion for the quarter. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BDX. Wells Fargo & Company raised their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $211.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, October 16th. Finally, Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.